Onkologie. 2011:5(3):131-137

Recent possibilities of myeloma bone disease diagnostics

Vlastimil Ščudla1, Miroslav Heřman2, Miroslav Mysliveček3
1 III. interní klinika FN a LF UP Olomouc
2 Radiologická klinika FN a LF UP Olomouc
3 Klinika nukleární medicíny FN a LF UP Olomouc

The paper presents recent opinion on individual imaging methods in the diagnostics of multiple myeloma (MM), and its differentiation

from monoclonal gammopathy of undetermined significance (MGUS). We assess the possibilities and difficulties in the differentiation

of individual manifestations of myeloma bone disease using conventional radiography, computed tomography (CT), magnetic resonance

imaging (including whole body MR), 99mTc-MIBI scintigraphy, and FDG-PET/CT which combines positron emission tomography and

multidetector computed tomography. We describe the contribution of new imaging methods for MM stratification (Durie-Salmon Plus

staging system), monitoring of the course of MM including therapeutics response, recognition of relapse/progression, and extramedular

progression of the disease. We also evaluate interpretation difficulties of individual imaging methods, and the principles of their

individual choice in specific clinical situations.

Keywords: multiple myeloma, monoclonal gammopathy of undetermined significance, conventional radiography, computed tomography, whole-body magnetic resonance, 99mTc-MIBI scintigraphy, positron emission tomography/computed tomography (FDG-PET/CT)

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ščudla V, Heřman M, Mysliveček M. Recent possibilities of myeloma bone disease diagnostics. Onkologie. 2011;5(3):131-137.
Download citation

References

  1. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23: 1545-1556. Go to original source... Go to PubMed...
  2. Ščudla V. Postižení pohybového systému u mnohočetného myelomu. In: Rovenský J, et al. Reumatológia v teórii a praxi VI. 1. vyd. Martin, Osveta, 2004: 582-638.
  3. Adam Z, Ševčík P, Vorlíček J, et al. Kostní nádorová choroba. 1. vydání Praha, Grada Publishing, 2005: 296.
  4. Healy JC, Armstrong P. Radiology of myeloma. In: Malphas JS, Bergsagel DE, Kyle RA. Myeloma-biology and management. 1st edit. Oxford, Oxford Med Publ 1995: 222-250.
  5. Hájek R, Adam Z, Maisnar V, et al. Česká myelomová skupina. Souhrn doporučení 2009, ,Diagnostika a léčba mnohočetného myelomu". Transfuze Hematol dnes 2009; 15(Suppl 2): 1-80.
  6. International Myeloma Working Group. Criteria for the clasification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121: 749-757. Go to original source... Go to PubMed...
  7. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127. Go to original source... Go to PubMed...
  8. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854. Go to original source...
  9. Mysliveček M, Nekula J, Bačovský J. Zobrazovací metody v diagnostice a sledování mnohočetného myelomu. Vnitř Lék 2006; 52: 46-54. Go to PubMed...
  10. Lütje S, de Rooy JWJ, Croockewit S, Koedam E, Oyen WJG, Raymakers RA. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009; 88: 1161-1168. Go to original source... Go to PubMed...
  11. Shortt CP, Gleeson TG, Breen KA, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR 2009; 192: 980-986. Go to original source... Go to PubMed...
  12. Fonti R, Salvatore B, Quarantelli M, et al. 18F-FDG PET/ CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008; 49: 195-200. Go to original source... Go to PubMed...
  13. Hur J, Yoon CS, Ryu YH, Yun J, Suh JS. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma. Acta Radiol 2008; 49: 427-435. Go to original source... Go to PubMed...
  14. Vaníček J, Krupa P, Adam Z. Přínos jednotlivých zobrazovacích metod pro diagnostiku a sledování aktivity mnohočetného myelomu. Vnitř Lék 2010; 56: 585-590. Go to PubMed...
  15. Hanrahan ChJ, Christensen CR, Crim JR. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. RadioGraphics 2010; 30: 127-142. Go to original source... Go to PubMed...
  16. Mulligan M, Smith S, Talmi D. Whole body radiography for bone survey screening of cancer and myeloma patients. Cancer Invest 2008; 26: 916-922. Go to original source... Go to PubMed...
  17. Nekula J, Mysliveček M, Bačovský J, et al. Magnetická rezonance a scintigrafie 99mTc-MIBI v diagnostice a sledování terapie mnohočetného myelomu. Čes Radiol 2004; 58: 65-70.
  18. Walker R, Jones-Jackson L, et al. Diagnostic imaging of multiple myeloma-FDG-PET and MRI, complementary for tracking short vs long term tumour response. Blood 2004; 104: 217a. Go to original source...
  19. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica Hematol J 2007; 92: 50-55. Go to original source... Go to PubMed...
  20. Hillengass J, Fechtner K, Zechmann CM, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009; 252: 477-485. Go to original source... Go to PubMed...
  21. Durie BGM. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006; 42: 1539-1543. Go to original source... Go to PubMed...
  22. Mechl M, Neubauer J, Krejčiřík P, Sedláková J. Celotělové vyšetření pomocí magnetické rezonance se zobrazením difuze u nemocných s mnohočetným myelomem - první zkušenosti. Čes Radiol 2007; 61: 364-369.
  23. Heřman M, Hrbek J, Ščudla V, et al. Korelace nálezů celotělového MR a stážovacího systému Durie/Salmon u pacientů s monoklonální gamapatií nejistého významu a mnohočetným myelomem. Čs Radiol 2010; 64: 203-212.
  24. Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28: 1606-1610. Go to original source... Go to PubMed...
  25. Pace L, Catalano L, Del Vecchio S, et al. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. Eur J Nucl Med 2001; 28: 304-312. Go to original source... Go to PubMed...
  26. Bacovsky J, Myslivecek M, Scudla V, et al. 99mTc-MIBI scintigraphy in multiple myeloma: prognostic value of different 99mTc-MIBI uptake patterns. Clin Nucl Med 2010; 35: 667-670. Go to original source... Go to PubMed...
  27. Bartel TB, Haessler J, Brown TLY, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114: 2068-2076. Go to original source... Go to PubMed...
  28. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol 2005; 184: 1199-1204. Go to original source... Go to PubMed...
  29. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9. Go to original source... Go to PubMed...
  30. Bäuerle T, Hillengass J, Fechtner K, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance whole body versus spinal MR imaging. Radiology 2009; 252: 477-485. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.